ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
Integration of single-cell regulon atlas and bulk RNA-seq for individualized prognostic prediction in stomach adenocarcinoma. [PDF]
Zhang A +5 more
europepmc +1 more source
Comprehensive analysis to develop a stromal senescence-associated gene signature for predicting hepatocellular carcinoma. [PDF]
Lu J, Zhang Z, Yuan W, Zhang Y.
europepmc +1 more source
Identification of Pancreatic Ductal Adenocarcinoma Extracellular Matrix Signatures from In-Depth Proteomic Profiling that Correlate with Lymphocyte Infiltration. [PDF]
Considine JM +8 more
europepmc +1 more source
Integrative Genomic Analysis Reveals Pseudouridine Modification-Related Gene Signatures Associated With Prognosis and Therapeutic Response Patterns in Hepatocellular Carcinoma. [PDF]
Gan Z, Fan T, Wang W, Qiao X, Zhao M.
europepmc +1 more source
Mutational signature-based classification uncovers emerging oral cancer subtypes with distinct molecular patterns. [PDF]
Deneuve S +19 more
europepmc +1 more source
Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma. [PDF]
Tang C +8 more
europepmc +1 more source

